Nadkarni Girish N, Horowitz Carol R
Department of Medicine, Division of Nephrology, Icahn School of Medicine, New York, NY; Department of Population Health Science and Policy, Icahn School of Medicine, New York, NY; and Department of Medicine, Icahn School of Medicine, New York, NY.
Department of Medicine, Division of Nephrology, Icahn School of Medicine, New York, NY; Department of Population Health Science and Policy, Icahn School of Medicine, New York, NY; and Department of Medicine, Icahn School of Medicine, New York, NY.
Adv Chronic Kidney Dis. 2016 Mar;23(2):120-4. doi: 10.1053/j.ackd.2016.01.017.
Recent advances in genomics and sequencing technology have led to a better understanding of genetic risk in CKD. Genetics could account in part for racial differences in treatment response for medications including antihypertensives and immunosuppressive medications due to its correlation with ancestry. However, there is still a substantial lag between generation of this knowledge and its adoption in routine clinical care. This review summarizes the recent advances in genomics and CKD, discusses potential reasons for its underutilization, and highlights potential avenues for application of genomic information to improve clinical care and outcomes in this particularly vulnerable population.
基因组学和测序技术的最新进展使人们对慢性肾脏病（CKD）的遗传风险有了更深入的了解。由于遗传学与血统相关，它在一定程度上可以解释包括抗高血压药物和免疫抑制药物在内的药物治疗反应中的种族差异。然而，从产生这些知识到将其应用于常规临床护理之间仍存在很大差距。本综述总结了基因组学和CKD的最新进展，讨论了其未得到充分利用的潜在原因，并强调了应用基因组信息改善这一特别脆弱人群的临床护理和治疗结果的潜在途径。
